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the end of 1st line CT, at the initiation and completion of second line 
CT and 12 and 18 months post baseline.
Results: 975 patients were enrolled between April 2003 and Sep-
tember 2004, with observations completed in March 2006. Median 
age was 65 yrs (32-90) with 28.3% of pts aged ≥ 70 yrs; 71.3% were 
male; 65.2% had stage IV disease. 487 pts experienced weight loss, 
172 lost >10% body weight in 4 weeks prior to the start of CT (79 
pts, 15.3% unknown). Overall baseline WHO PS was 0 (21.1%), 1 
(65.1%), 2 (10.0%), 3 (3.3%), 4 (0.5%). After 2 cycles of CT, WHO 
PS was unchanged for 57.6% (562) of pts (missing 99 pts); analysis by 
baseline WHO PS showed no change for 90 (44.3%) of pts with PS 0, 
423 (67.6%) PS 1, 32 (33.3%) PS 2, 14 (43.8%) PS 3 and 3 pts (60.0%) 
with baseline PS 4. Median duration of ﬁrst line CT was 3.0 months. At 
the end of 1st line chemotherapy PS was unchanged from baseline for 
41.2% of pts (missing 223 pts, 22.9%). Analysis by baseline PS shows 
no change for 64 (31.5%) of pts with baseline PS 0, 313 (50.0%) PS 1, 
14 (14.6%) PS 2, 9 (28.1%) PS 3, 2 (40%) PS 4. Improvement in PS 
during 1st line CT was seen in 66 (10.5%) of pts with baseline PS 1, 30 
(31.3%) PS 2, 5 (15.6%) PS 3, 2 (40%) PS 4. 285 pts were intended to 
receive 2nd line CT. At initiation of 2nd line CT, overall WHO PS was 
0 (11.3%), 1 (67.5%), 2 (17%), 3 (3.9%), 4 (0.4%). Median duration 
of 2nd line CT was 2.5 months. At the end of 2nd line CT, 254 patients 
had WHO PS 0 (6.8%), 1 (56.2%), 2 (17%), 3 (14.5%), 4 (5.5%) (no 
data 19 pts). 
Conclusion: The administration of CT to patients with PS 0 - 4 was 
recorded in this ﬁrst large-scale observational study of pts with ad-
vanced NSCLC. The majority of patients maintain PS after two cycles 
of 1st line CT. In those pts who received second line CT, a trend toward 
deteriorating PS is seen. The assessment of WHO PS is subjective. 
Maintenance or change in WHO PS may be driven by the impact of the 
cancer, chemotherapy treatment and/or any pre-existing co-morbidities. 
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Phase II trial of carboplatin plus docetaxel combined with a 
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Background: Preclinical and clinical studies showed that selective 
cyclooxygenase-2 (COX-2) inhibitor (celecoxib or rofecoxib) might 
improve efﬁcacy of treatment of advanced NSCLC. Meloxicam is 
a non-coxib, non-steroidal anti-inﬂammatory drug (NSAID), and 
selectively inhibits COX-2. Comparing with coxibs, meloxicam shows 
less cardiovascular toxicity; however, anti-tumor efﬁcacy has not been 
proved in clinical settings. The correlation between overexpression of 
COX-2 and chemotherapeutic response is also still controversial.
Methods: Eligibility criteria included stage IIIB/IV histologically or 
cytologically conﬁrmed non-small cell lung cancer, no prior chemo-
therapy, no current use of NSAIDs, PS = 0-1, and no urgent symptoms. 
Patients received oral meloxicam (150 mg) daily, and carboplatin 
(AUC 5) plus docetaxel (60 mg/m2) on day 1, every 3 weeks. Treat-
ment was continued until disease progression or toxicity. The primary 
endpoint was anti-tumor effect, with secondary endpoints including 
the safety. Calculated sample size was 45 patients (Simon’s two-stage 
minimax design). Tumor immunohistochemistry was performed for 
COX-2 and p27 in archival parafﬁn-embedded pre-treatment tumor tis-
sues. A semi-quantitative expression score was calculated on the basis 
of both percentage of positive tumor staining (COX-2 in cytoplasm, 
and p27 in cell nuclei) and staining intensity.
Results: From April 2005 to July 2006, a total of 50 patients (33 
males/17 females; median age, 65 years; ECOG PS, 0/1 = 24/26; tumor 
histology, adeno/squamous/other = 29/18/3; stage, IIIB/IV/recurrence 
= 16/32/2) were accrued and 47 patients were eligible. Partial response 
was 40% (95% CI 25-55%), stable disease was 38% (95% CI 23-
53%), and 19% had progressive disease. Grade 3/4 hematologic events 
included leukopenia (81%), neutropenia (96%), and thrombocytopenia 
(8%). Grade 3/4 non-hematologic events included hyponatremia (6%), 
anorexia (6%), fatigue (2%), angina (2%), skin rash (2%), and neuropa-
thy (2%). Febrile neutropenia occurred in 2 patients, and one patient 
developed pneumonia. Tumor tissues were available from 34 patients, 
and 32 samples were sufﬁcient for analysis. COX-2 expression corre-
lated with response rate (PR/SD+PD = 7/4 in high COX-2 score group, 
and 3/11 in low COX-2 score group; p<0.05, chi-square test). Response 
rate was not correlated with p27 status. There was no statistical associa-
tion between COX-2 and p27 expression.
Conclusions: Meloxicam added to carboplatin and docetaxel demon-
strated acceptable tolerability with encouraging activity in advanced 
NSCLC patients, especially in the patients with high COX-2 expres-
sion.
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Background: The efﬁcacy of PEM 500mg/m2 administered with 
vitamin B12 and folic acid (FS) in previously treated NSCLC has been 
established (Hanna 2004, N=571 [Study-W0]). The 500mg/m2 dose 
used in that study was selected based on the MTD for single-agent 
PEM without FS. Subsequent phase I studies in both western and 
Japanese study populations showed that single-agent PEM with FS was 
tolerated at doses of 900-1000mg/m2. The low toxicities in Study-W0 
and the tolerability of higher doses in the more recently completed dose 
escalation studies with FS led to studies comparing PEM 500mg/m2 to 
900 mg/m2 or 1000mg/m2 to determine whether a higher dose would 
provide additional efﬁcacy while maintaining an acceptable safety 
proﬁle. This work examines PEM ERRs and clinical study results from 
trials conducted in western and Japanese patients.
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Methods: Patients in a randomized phase III study conducted in 
western patients (Study-W1) received PEM 500mgm2 or 900mg/m2 
once every 3 weeks. Patients enrolled in a randomized phase II study 
conducted in Japan (Study-J1) received PEM 500mg/m2 or 1000mg/
m2 once every 3 weeks. Eligible patients in each of the studies had a 
histologic or cytologic diagnosis of NSCLC and had been previously 
treated. An established pharmacokinetic model was used to estimate 
AUCs from CrCL for patients in Study-W0 that received PEM 500mg/
m2 (N=265) and for patients in Study-J1. AUC was evaluated as a pre-
dictor of clinical efﬁcacy (survival, TTPD, PFS) to identify ERRs. The 
models included previously identiﬁed prognostic factors and inverse of 
mean daily AUC over the treatment period as covariates.
Results: Study-W1 did not show a survival advantage for the 900mg/
m2 (N=293) dose over the 500mg/m2 (N=295) dose. Study-J1 showed 
PEM 500mg/m2 (N=108) and 1000mg/m2 (N=108) to have similar 
efﬁcacy for Japanese patients with previously treated NSCLC. Of 
the efﬁcacy ERRs evaluated for Study-W0 and Study-J1, AUC was 
independently signiﬁcant only for TTPD in Study-W0 and was not 
signiﬁcant for other ERRs in either study (ERRs were not evaluated for 
Study-W1). There is internal consistency between the Study-J1 clinical 
results and the lack of ERRs for that study and external consistency 
between the Study-W1 clinical results and the lack of survival ERR for 
Study-W0.
Conclusion: Based on results available from two large randomized 
clinical trials and the evaluation of exposure-response relationships 
from a third trial, high dose PEM (900mg/mm2 or 1000mg/m2) does not 
offer an efﬁcacy advantage over the currently approved 500mg/m2 dose 
for either western or Japanese patient populations.
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Background: Optimal treatment for elderly patients with NSCLC has 
been under active investigation. This study evaluated the safety and 
initial efﬁcacy of a novel combination regimen of oral ﬂuoropyrimidine 
TS-1 plus gemcitabine (GEM) for elderly patients (pts) with advanced 
NSCLC.
Methods: A phase I/II trial in 11 centers examined TS-1 and GEM 
in pts with age ≥ 70, stage IIIB/IV previously untreated NSCLC. The 
starting dose was 60 mg/day (day 1-14) for TS-1 and 800 mg/m2 for 
GEM (day 8, 15). GEM was increased to 1000 mg/m2 at dose level 2 
and TS-1 was increased to 80 mg/day at dose level 3. Phase II portion 
of the study assessed the efﬁcacy and tolerability of the combination 
regimen at the dose determined in the phase I portion. The primary 
endpoint was objective response rate.
Results: Twenty two pts were enrolled in the phase I portion: 6 pts on 
dose level 1, 10 on dose level 2 and 6 on dose level 3. Median age of 
this group was 75 yrs (range 70-85). Dose limiting toxicities included 
Gr. 4 neutropenia (2 pts) and Gr.3 skin toxicity (4 pts). The recom-
mended dose (RD) was TS-1 60 mg/day and GEM 1000 mg/m2, with 
which 20 pts were subsequently treated in the phase II portion. The me-
dian age of 30 pts treated with the RD was 76 yrs (range 70-85). Grade 
(Gr) 3/4 toxicities include neutropenia (12 pts; 7 with Gr 4), thrombo-
cytopenia (4 pts; 0 with Gr 4), skin toxicity (8 pts), thrombus (1 pt) and 
peumonitis (2 pts). Nine patients (30%, 95% conﬁdence interval [CI] 
= 14 to 46%) had partial responses and 16 (53%, 95% CI = 35 to 71%) 
had stable disease. 
Conclusion: Encouraging antitumor activity and safety of TS-1 plus 
gemcitabine support further development of this combination therapy 
for elderly patients with advanced NSCLC.
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Background: Carboplatin AUC 5 d1-Gemcitabine 1250 mg/m2 d1, 8 
is an approved standard regimen in advanced NSCLC. Hematologic 
toxicity is however frequent; thrombocytopenia is found in more than 
40 % of cases, neutropenia in 20%.
Aim: to investigate in two equally dose-dense regimens, whether the 
toxicity of the Gemcitabine-Carboplatin combination could be reduced 
by administering Carboplatin on day 8 instead of day 1 and without 
change in response rate.
Methods: Patients in arm A are treated with Gemcitabine (1250 mg/m2 
days 1,8) and Carboplatin (AUC 5 day 1) Patients in arm B are treated 
with Gemcitabine (1250 mg/m2 days 1,8) and Carboplatin (AUC 5 day 
8. ) Drugs are administered over a 21-day cycle, on an outpatient basis. 
Toxicity and response are evaluated weekly and every second cycle, 
respectively. 
Statistics: The hypothesis of the study protocol is that regimen B 
shows a decrease in toxicity of 50% without loss of response rates. 
Toxicity is deﬁned as a thrombocytopenia and/or neutropenia grade ı. 
The Bryan and Day design allows to consider both response and toxic-
ity as primary endpoint. With an alpha of 0.10 and a power of 90% the 
sample size was estimated to be 67 patients in each arm. An interim 
analysis was performed after 54 included patients, 27 in each arm. 
Results: A total of 71 patients were enrolled between April 2004 and 
March 2006, before the study was prematurely stopped because data 
showed a statistical signiﬁcant difference in toxicity. Patient and dis-
ease characteristics for the 69 eligible patients are summarized in Table 
1. Toxicity and response are reported in Table 2.
